Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.67 |
| ▸ | TP53 | P04637 | 6/20 | 0.67 |
| ▸ | KMO | O15229 | 1/20 | 0.67 |
| ▸ | NPC1 | O15118 | 7/20 | 0.66 |
| ▸ | RAB9A | P51151 | 7/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.66 |
| ▸ | CHRNA5 | P30532 | 4/20 | 0.66 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.66 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | MAOA | P21397 | 1/20 | 0.60 |
| ▸ | BLVRB | P30043 | 1/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1422372 | 0.95 | KMO (0.67) | SMN1; SMN2TP53KMONPC1RAB9A | |
| SCHEMBL61063 | 0.86 | NPC1 (0.69) | SMN1; SMN2TP53KMONPC1RAB9A | |
| SCHEMBL12171589 | 0.86 | SMN1; SMN2 (0.75) | SMN1; SMN2TP53NPC1RAB9ACHRNB2 | |
| SCHEMBL60427 | 0.86 | NPC1 (0.76) | SMN1; SMN2TP53KMONPC1RAB9A | |
| SCHEMBL4456727 | 0.84 | CA9 (0.55) | SMN1; SMN2TP53KMONPC1RAB9A | |
| SCHEMBL4456725 | 0.84 | CA9 (0.55) | SMN1; SMN2TP53KMONPC1RAB9A | |
| SCHEMBL59247 | 0.83 | RAB9A (0.72) | SMN1; SMN2TP53KMONPC1RAB9A | |
| SCHEMBL17336565 | 0.83 | NPC1 (0.72) | SMN1; SMN2TP53KMONPC1RAB9A | |
| SCHEMBL12171569 | 0.83 | NPC1 (0.76) | SMN1; SMN2TP53KMONPC1RAB9A | |
| SCHEMBL1422479 | 0.83 | CHRNB2 (0.64) | SMN1; SMN2TP53NPC1RAB9ACHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 434 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4851933-B2 | — | — | 2012-01-11 | — | — | JP | claimed |
| EP-1689737-B1 | BETA-LACTAMS FOR THE TREATMENT OF CNS DISORDERS | GLAXO GROUP LTD (GB) | 2008-07-16 | — | — | EP | claimed |
| EP-1618098-A4 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PCT THERAPEUTICS INC (US) | 2008-07-16 | — | — | EP | claimed |
| US-7304080-B2 | E.g., 3-[5-(2-Chloro-pyridin-3-yl)-[1,2,4]oxadiazol-3-yl]-benzoic acid; treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay such as genetic disorders | PTC THERAPEUTICS, INC. (US) | 2007-12-04 | — | — | US | claimed |
| US-20060148863-A1 | E.g., 3-[5-(2-Chloro-pyridin-3-yl)-[1,2,4]oxadiazol-3-yl]-benzoic acid; treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay such as genetic disorders | PTC THERAPEUTICS, INC. | 2006-07-06 | — | — | US | claimed |
| US-20060035943-A1 | E.g., 3-(5-p-tolyl-[1,2,4]oxadiazol-3-yl)-benzoic acid; treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay such as genetic disorders | PTC THERAPEUTICS, INC. | 2006-02-16 | — | — | US | claimed |
| EP-1618098-A2 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PCT Therapeutics Inc. (US) | 2006-01-25 | — | — | EP | claimed |
| WO-2004091502-A2 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS | PTC THERAPEUTICS, INC. (US) | 2004-10-28 | — | — | WO | claimed |
| US-20040204461-A1 | translation of mRNA is allowed to continue past a nonsense mutation point, resulting in the production of a full length protein; genetic disorders; 3-(5-p-tolyl-[1,2,4]oxadiazol-3-yl)-benzoic acid | PTC THERAPEUTICS, INC. | 2004-10-14 | — | — | US | claimed |
| US-12043689-B2 | Nickel catalysts with single metal cations for homopolymerization and copolymerization | UNIVERSITY OF HOUSTON SYSTEM (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043688-B2 | Nickel catalysts with two alkali ions for homopolymerization and copolymerization | UNIVERSITY OF HOUSTON SYSTEM (US) | 2024-07-23 | — | — | US | disclosed |
| EP-4374928-A2 | NOVEL ALK2 INHIBITORS AND METHODS FOR INHIBITING BMP SIGNALING | The Brigham And Women's Hospital Inc. (US) | 2024-05-29 | — | — | EP | disclosed |
| US-20240166775-A1 | NICKEL CATALYSTS WITH TWO METAL CATIONS FOR HOMOPOLYMERIZATION AND COPOLYMERIZATION | UNIVERSITY OF HOUSTON SYSTEM (US) | 2024-05-23 | — | — | US | disclosed |
| US-20240158439-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II HLA-DRB1*15:01 MOLECULES WITH ENHANCED METABOLIC STABILITY | PROVID PHARMACEUTICALS INC. | 2024-05-16 | — | — | US | disclosed |
| WO-2003075917-A1 | COMBINATION THERAPY FOR TREATING, PREVENTING OR MANAGING PROLIFERATIVE DISORDERS AND CANCERS | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-09-18 | — | — | WO | disclosed |
| US-20030119754-A1 | Benzimidazole compounds and antiviral uses thereof | TRIMERIS, INC. | 2003-06-26 | — | — | US | disclosed |
| US-20030073732-A1 | Isothiazoloanthrones, isoxazoloanthrones, isoindolanthrones and derivatives thereof as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, INC. | 2003-04-17 | — | — | US | disclosed |
| WO-2002066450-A2 | ANTHRONE DERIVATIVES AND THEIR USE AS INK INHIBITORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2002-08-29 | — | — | WO | disclosed |
| EP-1218347-A1 | PYRAZOLOANTHRONE AND DERIVATIVES THEREOF AS JNK INHIBITORS AND THEIR COMPOSITIONS | SIGNAL PHARMACEUTICALS, INC. (US) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001012609-A1 | PYRAZOLOANTHRONE AND DERIVATIVES THEREOF AS JNK INHIBITORS AND THEIR COMPOSITIONS | SIGNAL PHARMACEUTICALS, INC. (US) | 2001-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158439-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II HLA-DRB1*15:01 MOLECULES WITH ENHANCED METABOLIC STABILITY | HLA-DRB1, HLA-B, HLA-C | SMN1; SMN2 2759/4885TP53 143/4885KMO 434/4885 |
| US-20060035943-A1 | E.g., 3-(5-p-tolyl-[1,2,4]oxadiazol-3-yl)-benzoic acid; treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay such as genetic disorders | UPF1, PABPC1, PABPC4 | SMN1; SMN2 19/4885TP53 2818/4885KMO 3017/4885 |
| US-20030119754-A1 | Benzimidazole compounds and antiviral uses thereof | MAVS, ZC3HAV1, TIMM13 | SMN1; SMN2 1189/4885TP53 3577/4885KMO 2340/4885 |
| US-20060148863-A1 | E.g., 3-[5-(2-Chloro-pyridin-3-yl)-[1,2,4]oxadiazol-3-yl]-benzoic acid; treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay such as genetic disorders | UPF1, PABPC1, PABPC4 | SMN1; SMN2 13/4885TP53 3336/4885KMO 2630/4885 |
| US-20040204461-A1 | translation of mRNA is allowed to continue past a nonsense mutation point, resulting in the production of a full length protein; genetic disorders; 3-(5-p-tolyl-[1,2,4]oxadiazol-3-yl)-benzoic acid | UPF1, PABPC1, PABPC4 | SMN1; SMN2 88/4885TP53 2360/4885KMO 2803/4885 |
| US-20030073732-A1 | Isothiazoloanthrones, isoxazoloanthrones, isoindolanthrones and derivatives thereof as JNK inhibitors and compositions and methods related thereto | MAP3K7, MAPKAPK2, MAP3K2 | SMN1; SMN2 4178/4885TP53 944/4885KMO 597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.